How to buy Surmodics stock | $39.21

Surmodics, Inc is a diagnostics & research business based in the US. Surmodics shares (SRDX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Surmodics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Surmodics. Find the stock by name or ticker symbol: SRDX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Surmodics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$39.21, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Surmodics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Surmodics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Surmodics share price

Use our graph to track the performance of SRDX stocks over time.

Surmodics shares at a glance

• Key figures

Information last updated 2020-11-30.

Latest market close	USD$39.21
52-week range	USD$22.06 - USD$49
50-day moving average	USD$38.9809
200-day moving average	USD$41.5174
Wall St. target price	USD$64.25
PE ratio	474.0625
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.08

Buy Surmodics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Surmodics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Surmodics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Surmodics price performance over time

Historical closes compared with the close of $39.21 from 2020-12-09

1 week (2021-01-06)	-14.69%
1 month (2020-12-14)	2.03%
3 months (2020-10-13)	-7.85%
6 months (2020-07-13)	-6.64%

1 year (2020-01-13)	-2.95%
2 years (2019-01-13)	N/A
3 years (2018-01-13)	N/A
5 years (2016-01-13)	113.91%

Is Surmodics under- or over-valued?

Valuing Surmodics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surmodics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Surmodics's P/E ratio

Surmodics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 474x. In other words, Surmodics shares trade at around 474x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Surmodics's PEG ratio

Surmodics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 78.9833. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Surmodics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Surmodics's EBITDA

Surmodics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.9 million.

The EBITDA is a measure of a Surmodics's overall financial performance and is widely used to measure a its profitability.

Surmodics financials

Revenue TTM	USD$94.9 million
Gross profit TTM	USD$29.4 million
Return on assets TTM	-0.48%
Return on equity TTM	0.89%
Profit margin	1.18%
Book value	$9.609
Market capitalisation	USD$517.7 million

TTM: trailing 12 months

Shorting Surmodics shares

There are currently 347,241 Surmodics shares held short by investors – that's known as Surmodics's "short interest". This figure is 1% up from 343,939 last month.

There are a few different ways that this level of interest in shorting Surmodics shares can be evaluated.

Surmodics's "short interest ratio" (SIR)

Surmodics's "short interest ratio" (SIR) is the quantity of Surmodics shares currently shorted divided by the average quantity of Surmodics shares traded daily (recently around 37867.066521265). Surmodics's SIR currently stands at 9.17. In other words for every 100,000 Surmodics shares traded daily on the market, roughly 9170 shares are currently held short.

However Surmodics's short interest can also be evaluated against the total number of Surmodics shares, or, against the total number of tradable Surmodics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surmodics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Surmodics shares in existence, roughly 30 shares are currently held short) or 0.0314% of the tradable shares (for every 100,000 tradable Surmodics shares, roughly 31 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Surmodics.

Find out more about how you can short Surmodics stock.

Surmodics share dividends

We're not expecting Surmodics to pay a dividend over the next 12 months.

Have Surmodics's shares ever split?

Surmodics's shares were split on a 2:1 basis on 7 December 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Surmodics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Surmodics shares which in turn could have impacted Surmodics's share price.

Surmodics share price volatility

Over the last 12 months, Surmodics's shares have ranged in value from as little as $22.06 up to $49. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surmodics's is 1.0688. This would suggest that Surmodics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Surmodics overview

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Frequently asked questions

• What percentage of Surmodics is owned by insiders or institutions?

  Currently 3.304% of Surmodics shares are held by insiders and 90.284% by institutions.

• When does the fiscal year end for Surmodics?

  Surmodics's fiscal year ends in September.

• Where is Surmodics based?

  Surmodics's address is: 9924 West 74th Street, Eden Prairie, MN, United States, 55344

• What is Surmodics's ISIN number?

  Surmodics's international securities identification number is: US8688731004

• What is Surmodics's CUSIP number?

  Surmodics's Committee on Uniform Securities Identification Procedures number is: 868873100